Revolution Medicines (NASDAQ:RVMD) Stock Price Expected to Rise, HC Wainwright Analyst Says

Revolution Medicines (NASDAQ:RVMD - Get Free Report) had its target price upped by research analysts at HC Wainwright from $72.00 to $73.00 in a research note issued on Monday,Benzinga reports. The brokerage presently has a "buy" rating on the stock. HC Wainwright's target price points to a potential upside of 86.13% from the stock's previous close. HC Wainwright also issued estimates for Revolution Medicines' Q1 2025 earnings at ($1.09) EPS, Q2 2025 earnings at ($1.12) EPS, Q3 2025 earnings at ($1.14) EPS, Q4 2025 earnings at ($1.17) EPS and FY2025 earnings at ($4.51) EPS.

A number of other brokerages also recently commented on RVMD. Needham & Company LLC reduced their target price on shares of Revolution Medicines from $60.00 to $59.00 and set a "buy" rating for the company in a report on Thursday, February 27th. UBS Group lifted their price target on shares of Revolution Medicines from $65.00 to $71.00 and gave the stock a "buy" rating in a report on Wednesday, January 8th. JPMorgan Chase & Co. increased their price objective on Revolution Medicines from $63.00 to $71.00 and gave the company an "overweight" rating in a report on Tuesday, December 3rd. Guggenheim boosted their target price on Revolution Medicines from $82.00 to $87.00 and gave the stock a "buy" rating in a research note on Tuesday, December 3rd. Finally, Wedbush reissued an "outperform" rating and issued a $67.00 price target on shares of Revolution Medicines in a report on Thursday, February 27th. Twelve research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of "Buy" and an average target price of $66.31.

Remove Ads

Revolution Medicines Trading Down 1.0 %

Shares of RVMD traded down $0.40 during mid-day trading on Monday, hitting $39.22. The company's stock had a trading volume of 1,460,805 shares, compared to its average volume of 1,343,317. The firm has a market capitalization of $7.29 billion, a price-to-earnings ratio of -10.92 and a beta of 1.46. The company's 50-day moving average is $41.81 and its 200-day moving average is $46.10. Revolution Medicines has a 52-week low of $29.55 and a 52-week high of $62.40.

Revolution Medicines (NASDAQ:RVMD - Get Free Report) last announced its earnings results on Wednesday, February 26th. The company reported ($1.12) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.01) by ($0.11). As a group, sell-side analysts predict that Revolution Medicines will post -3.49 earnings per share for the current fiscal year.

Insider Activity at Revolution Medicines

In other Revolution Medicines news, insider Mark A. Goldsmith sold 11,714 shares of the business's stock in a transaction that occurred on Monday, December 16th. The stock was sold at an average price of $45.40, for a total value of $531,815.60. Following the completion of the transaction, the insider now directly owns 325,056 shares of the company's stock, valued at approximately $14,757,542.40. The trade was a 3.48 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CFO Jack Anders sold 2,635 shares of the firm's stock in a transaction that occurred on Monday, December 16th. The stock was sold at an average price of $45.40, for a total transaction of $119,629.00. Following the sale, the chief financial officer now directly owns 96,470 shares in the company, valued at $4,379,738. The trade was a 2.66 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 18,678 shares of company stock worth $847,981 over the last three months. Company insiders own 8.00% of the company's stock.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of RVMD. IFP Advisors Inc acquired a new position in Revolution Medicines in the 4th quarter worth about $34,000. Quarry LP purchased a new stake in shares of Revolution Medicines in the third quarter valued at approximately $82,000. Sterling Capital Management LLC raised its stake in shares of Revolution Medicines by 588.7% during the 4th quarter. Sterling Capital Management LLC now owns 1,956 shares of the company's stock worth $86,000 after buying an additional 1,672 shares during the period. Farther Finance Advisors LLC lifted its position in shares of Revolution Medicines by 368.3% during the 4th quarter. Farther Finance Advisors LLC now owns 2,051 shares of the company's stock valued at $90,000 after buying an additional 1,613 shares in the last quarter. Finally, Kapitalo Investimentos Ltda acquired a new stake in Revolution Medicines in the 4th quarter valued at $104,000. Institutional investors and hedge funds own 94.34% of the company's stock.

About Revolution Medicines

Revolution Medicines, Inc, a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies.